We collected information about Intellia Therapeutics Inc Hours for you. Follow the liks to find out everything about Intellia Therapeutics Inc Hours.
https://www.intelliatx.com/
Intellia Therapeutics Announces Expansion of Ongoing Phase 1 Study of NTLA-2001 to Include Adults with Transthyretin Amyloidosis with Cardiomyopathy (ATTR-CM) Overview Intellia is a pioneer in the development of CRISPR/Cas9 genome editing and is rapidly moving experimental therapies towards the clinic.
https://www.intelliatx.com/contact/
https://www.barrons.com/market-data/stocks/ntla
Complete Intellia Therapeutics Inc. stock information by Barron's. View real-time NTLA stock price and news, along with industry-best analysis. ... Before Hours Vol. 953. Price at close $111.73-1 ...
https://www.marketbeat.com/instant-alerts/nasdaq-ntla-consensus-analyst-rating-2021-11-2-3/
Brokerages expect that Intellia Therapeutics, Inc. (NASDAQ:NTLA) will announce $10.31 million in sales for the current quarter, Zacks reports. Eight analysts have issued estimates for Intellia Therapeutics' earnings. The lowest sales estimate is $4.67 million and the highest is $28.98 million. Intel
https://www.nasdaq.com/market-activity/stocks/ntla
Intellia Therapeutics, Inc. Common Stock (NTLA) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.
https://www.barrons.com/market-data/stocks/ntla/research-ratings
Intellia Therapeutics Inc. research and ratings by Barron's. View NTLA revenue estimates and earnings estimates, as well as in-depth analyst breakdowns. ... Before Hours Vol. 19. Price at close ...
https://www.marketwatch.com/investing/stock/ntla
Intellia Therapeutics price target raised to $168 from $106 at Raymond James, stock rated outperform. Jun. 29, 2021 at 7:37 a.m. ET by Tonya Garcia.
https://www.nasdaq.com/articles/do-institutions-own-intellia-therapeutics-inc.-nasdaq%3Antla-shares-2021-10-28
Intellia Therapeutics has a market capitalization of US$9.5b, so it's too big to fly under the radar. We'd expect to see both institutions and retail investors owning a …
https://www.fool.com/investing/2021/11/21/do-crispr-therapeutics-and-intellia-face-a-big-saf/
CRISPR gene editing is promising, but there's a risk that it can cause unwanted mutations. Intellia Therapeutics ( NTLA -8.11% ) and CRISPR Therapeutics ( CRSP -8.80% ) are pioneers in developing ...
https://finance.yahoo.com/news/intellia-therapeutics-inc-ntla-dips-215009453.html
Intellia Therapeutics, Inc. (NTLA) closed the most recent trading day at $132.37, moving -1.22% from the previous trading session. This change lagged the …
Searching for Intellia Therapeutics Inc Hours?
You can just click the links above. The info is collected for you.
